公开(公告)号：US20210100892A1

公开(公告)日：2021-04-08

申请号：US16737546

申请日：2020-01-08

申请人： Jian Qing XU ,  Xiao Yan ZHANG ,  Jing WANG ,  Ling Yan ZHU ,  Beverly W. LUBIT

发明人： Jian Qing XU ,  Xiao Yan ZHANG ,  Jing WANG ,  Ling Yan ZHU ,  Beverly W. LUBIT

IPC分类号： A61K39/145 ,  C12N15/86 ,  C12N7/00

摘要： The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against pathogensthat is tailored to elicit a broad T cell response targeting conserved viral epitopes. The universal vaccines are prepared against an immunogen of an infectious pathogenic organism selected from a virus, a bacteria, a fungus or a protozoan comprising at least one ribonucleic acid (RNA) polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in CD8+ T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in a humanized mouse model comprising a fully functional human immune system.

公开(公告)号：US20220347287A1

公开(公告)日：2022-11-03

申请号：US17837861

申请日：2022-06-10

申请人： Jian Qing Xu ,  Xiao Yan ZHANG ,  Jing WANG ,  Ling Yan ZHU ,  Beverly W. LUBIT

发明人： Jian Qing Xu ,  Xiao Yan ZHANG ,  Jing WANG ,  Ling Yan ZHU ,  Beverly W. LUBIT

IPC分类号： A61K39/145 ,  C12N7/00 ,  C12N15/86

摘要： The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes. The universal vaccines are prepared against an immunogen of an infectious pathogenic organism selected from a virus, a bacteria, a fungus or a protozoan comprising at least one ribonucleic acid (RNA) polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in CD8+ T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in a humanized mouse model comprising a fully functional human immune system.